Evidence map›Paper›PMID 32631505›Full record

ArticleBioorganic & medicinal chemistry letters2020

N-[

Jason R Buck, Samir Saleh, Trey Claus, Christine Lovly, Matthew R Hight, Michael L Nickels, M Noor Tantawy, H Charles Manning

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jason R BuckVanderbilt Center for Molecular Probes, United States; Vanderbilt University, Institute of Imaging Science, United States; Vanderbilt University Medical Center, United States.
Samir SalehVanderbilt Center for Molecular Probes, United States; Vanderbilt University, Institute of Imaging Science, United States; Vanderbilt University Medical Center, United States.
Trey ClausVanderbilt Center for Molecular Probes, United States; Vanderbilt University, Institute of Imaging Science, United States; Vanderbilt University Medical Center, United States.
Christine LovlyVanderbilt University Medical Center, United States; Vanderbilt Ingram Cancer Center, United States; Department of Hematology and Oncology, Vanderbilt University Medical Center, United States.
Matthew R HightVanderbilt Center for Molecular Probes, United States; Vanderbilt University, Institute of Imaging Science, United States; Vanderbilt University Medical Center, United States.
Michael L NickelsVanderbilt Center for Molecular Probes, United States; Vanderbilt University, Institute of Imaging Science, United States; Vanderbilt University Medical Center, United States; Mallinckrodt Institute of Radiology, Washington University School of Medicine, United States.
M Noor TantawyVanderbilt University, Institute of Imaging Science, United States; Vanderbilt University Medical Center, United States.
H Charles ManningVanderbilt Center for Molecular Probes, United States; Vanderbilt University, Institute of Imaging Science, United States; Vanderbilt University Medical Center, United States; Department of Radiology, Vanderbilt University Medical Center, United States. Electronic address: henry.c.manning@vanderbilt.edu.

Funding

TISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7M
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal CancerP50CA236733 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Robert J. Coffey · 2019 to 2026
$19.6M
VU PREDICTU24CA220325 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KOPETZ, SCOTT, MANNING, HENRY CHARLES · 2018 to 2022
$3.3M
PET System for Preclinical ResearchS10OD016245 · OD · VANDERBILT UNIVERSITY · PI PETERSON, TODD E · 2013 to 2013
$584k
Radiofluorination Equipment for PET Imaging ResearchS10OD019963 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MANNING, HENRY CHARLES · 2016 to 2016
$291k
NCI NIH HHS P50 CA098131NCI NIH HHS P50 CA236733NCI NIH HHS U24 CA220325NIH HHS S10 OD016245NIH HHS S10 OD019963
6 · The paper itself

Abstract

N-[

Indexed as

Molecular ImagingPositron-Emission TomographyAnaplastic Lymphoma KinaseCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationCrizotinibDose-Response Relationship, DrugFluorine RadioisotopesHumansLung NeoplasmsMolecular StructureProtein Kinase InhibitorsStructure-Activity RelationshipALK protein, humanAnaplastic Lymphoma KinaseCrizotinibFluorine-18Fluorine RadioisotopesProtein Kinase InhibitorsCancerCrizotinibNSCLCPETTherapy

Identifiers

PMID32631505
PMCPMC7357882

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.